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Skeletal myogenesis, like hematopoiesis, occurs in
successive developmental stages that involve dif-
ferent cell populations and expression of different
genes. We show here that the transcription factor
nuclear factor one X (Nfix), whose expression is acti-
vated by Pax7 in fetal muscle, in turn activates the
transcription of fetal specific genes such as MCK
and b-enolase while repressing embryonic genes
such as slow myosin. In the case of the MCK
promoter, Nfix forms a complex with PKC theta that
binds, phosphorylates, and activates MEF2A. Pre-
mature expression of Nfix activates fetal and sup-
presses embryonic genes in embryonic muscle,
whereas muscle-specific ablation of Nfix prevents
fetal and maintains embryonic gene expression in
the fetus. Therefore, Nfix acts as a transcriptional
switch from embryonic to fetal myogenesis.INTRODUCTION
During skeletal myogenesis, stage-specific transcriptional
changes occur in muscle fibers derived from differentiation of
different precursors: embryonic, fetal myoblasts and satellite
cells (Biressi et al., 2007a; Stockdale, 1992). ‘‘Embryonic’’ or
primary fibers appear at E11 in the mouse and establish the
basic muscle pattern. A second wave of myogenesis, termed
fetal or secondary, takes place between E14.5 and E17.5 and
involves the fusion of fetal myoblasts either with each other to
form secondary fibers (initially smaller and surrounding primary554 Cell 140, 554–566, February 19, 2010 ª2010 Elsevier Inc.fibers), or with primary fibers. At E16, satellite cells appear as
mononucleated cells underneath the newly formed basal lamina
of each individual fiber: they are responsible for muscle postnatal
growth and regeneration. Previous work identified specific
features of embryonic, fetal myoblasts and satellite cells and of
themyotubes they give rise to (Biressi et al., 2007a). In particular,
primary fibers express both slow and embryonic fast MyHCs
and ubiquitous isoforms of metabolic enzymes. Conversely,
secondary fibers express fast but not slow MyHC and muscle-
specific enzymes such as MCK, b-enolase and PKCq (Biressi
et al., 2007a).
A genome-wide expression analysis on purified embryonic
and fetal myoblasts (Biressi et al., 2007b) revealed that the tran-
scription factor nuclear factor I X (Nfix) is robustly expressed in
the fetus but absent in the embryo. Nuclear factor one (Nfi)
proteins act as transcriptional activators and/or repressors of
cellular and viral genes. In amniotes, the Nfi gene family consists
of four closely related genes, named Nfia, Nfib, Nfic, and Nfix
(Gronostajski, 2000). They encode for proteins with a conserved
N-terminal DNA-binding and dimerization domain and a
C-terminal transactivation/repression domain, which exhibits a
high variability due to extensive alternative splicing. Nfi family
members act as homo- and heterodimers and bind with high
affinity to the palindromic consensus sequence 50-PyTGGCA-
N3-TGCCAPu-30. Nfi binding motifs were detected in promoters
of genes expressed in different organs, including brain, lung,
liver, intestine, muscle, connective tissue, and skeletal elements
(Gronostajski, 2000); recently Nfia was shown to regulate fate
choice between erythrocytes and granulocytes (Starnes et al.,
2009).
Gene ablation studies revealed that Nfi genes have essential
and distinct roles in different organ systems including brain (Nfia)
(das Neves et al., 1999); lung and brain (Nfib) (Steele-Perkins
et al., 2005); tooth (Nfic) (Steele-Perkins et al., 2003); and brain,
intestine, and skeleton (Nfix) (Driller et al., 2007). Nf1-binding
sites are present on the Myogenin promoter (Johanson et al.,
1999) andNfi can form a complexwithMyogenin, thus increasing
its affinity for a number of muscle-specific genes (Funk and
Wright, 1992). This suggested a role for Nfi as co-factor inmuscle
differentiation but its precise function was not subsequently
studied. We investigated the function of Nfix during mammalian
myogenesis and report here that Nfix represses the expression
of embryonic genes while activating fetal genes in developing
skeletal muscle; thus it acts as a main regulator of the embryonic
to fetal transcriptional switch, a role that has evolutionary signif-
icance in amniotes.
RESULTS
Nfix2 Represses Embryonic and Activates Fetal Muscle
Genes
Although the pattern of embryonic, fetal, and adult gene expres-
sion in skeletal muscle has been described (Gunning and Harde-
man, 1991), the underlying molecular control remains elusive.
A genome-wide screen in fetal and embryonic myoblasts
purified from Myf5GFP-P/+ mice (Biressi et al., 2007b) identified
the transcription factor nuclear factor one among the differen-
tially expressed genes; in particular Nfix appeared as the most
differentially expressed (>8-fold change) being abundant in the
fetus and virtually absent in the embryo (Figures S1A–S1C avail-
able online). Of the various splicing isoforms, we focused on the
best characterized, Nfix2, which was shown to transactivate
expression of a variety of promoters in fibroblasts, glial cells,
and other cell types (Chaudhry et al., 1998) and is strongly
expressed in fetal skeletal muscle (Figure S1D). To investigate
the possible role of Nfix in fetal myogenesis, we initially per-
formed loss-of-function experiments (dominant negative Nfi-
engrailed) in fetal myoblasts and gain of function experiments
(expression ofNfix2 isoform) in embryonicmyoblasts. As amodel
of fetal myogenesis, we initially used the myogenic cell line
C2C12, which allows more in-depth biochemical analysis than
in purified fetal myoblasts, which are limited in amount. Although
derived from postnatal muscle, C2C12 cells sharemany features
with fetal myoblasts, including the expression of high levels of
Nfix (Biressi et al., 2007b) (Figure S1A). C2C12 cells were trans-
duced with a lentiviral vector expressing the dominant-negative
Nfi-engrailed (NfiEngr), containing the DNA binding and dimer-
ization domain of Nfia fused together with the Drosophila Engr
transcriptional repression domain that inhibitis transactivation
activity of all Nfi proteins (Bachurski et al., 2003). A lentivirus
expressing only the engrailed domain was used as control
(Engr). As shown in Figure S1E, Nfi inhibition negatively affects
myogenesis, likely because of reduced Myogenin expression
and consequent reduced expression of Myosin Heavy Chains
and MCK (Figure S1F). These data are consistent with previous
studies (Funk and Wright, 1992; Johanson et al., 1999). BrdU
incorporation indicated that in C2C12 cells the NfiEngr block of
terminal differentiation was not accompanied by enhanced
proliferation rate (data not shown). To test whether a possible
modulation of embryonic and fetal gene expression might exist
independently of a generic inhibition of terminal differentiationin the whole culture, we analyzed embryonic/fetal-specific
gene expression in the few differentiated C2C12NfiEngr myo-
tubes. We used the short trypsinization method (Kitzmann
et al., 1998), which causes detachment of myotubes from sub-
strate at a low dose of trypsin. C2C12Engr and C2C12NFIEngr
differentiated myotubes (DM mt) were collected and analyzed
by western blot in comparison with the whole differentiated
culture (DM). As shown in Figure S1G, the C2C12NFIEngr myo-
tubes express total sarcomeric MyHC at levels comparable to
Engr controls, but show a strongly reduced expression of fetal
markers such as MCK and b-enolase. Conversely, slow MyHC,
normally repressed during fetal myogenesis and almost absent
in control C2C12 is expressed at high levels. We repeated these
experiments onMyf5GFP-P/+-purified fetal myoblasts, whichwere
infected by LentiNfiEngr or Engr, as a control. NfiEngr causes
a less dramatic inhibition of differentiation (e.g., MyHC expres-
sion) in fetal myoblasts than in the C2C12 cells (Figures S1E
and S1H). Nevertheless, NfiEngr-expressing fetal myoblasts
acquire the typical aspect of their embryonic counterparts,
characterized by smaller myotubes and a lower number of
nuclei/myotube (data not shown); in addition, western blot
analysis confirmed that the two fetal markers analyzed, MCK
and b-enolase, were strongly downregulated, whereas slow
MyHCwas robustly induced in fetal myotubes (Figure S1I). Since
NfiEngr blocks the function of all the members of the Nfi family,
we investigated whether the effect on fetal myogenesis was
specific to Nfix. Fetal myoblasts were isolated by cell sorting
from the Nfix null//Myf5GFP-P/+ mouse embryos (described
below). In addition, small interfering RNA (siRNA) silencing of
Nfix and Nfia was also performed. Myf5GFP-P/+-purified fetal
myoblasts were transduced with lentivectors expressing siNfix,
siNfia, or the nontargeting control siRNA (CTL). As Figure 1D
shows, the inhibition of both Nfix and Nfia does not modulate
the expression of the other members of the family, suggesting
the absence of reciprocal regulation among the Nfi proteins.
Most importantly, the selective inhibition of Nfix, both in the
Nfix null myoblasts and in the Nfix silenced cells, dramatically
impairs fetal myoblast differentiation and fusion (Figures 1A
and 1E) and abolishes the expression of MCK and b-enolase
(Figure 1C); despite reduced differentiation, slow MyHC was
activated in the Nfix null and siNfix myotubes. Silencing of Nfia
did not inhibit myogenesis and did not modify the profile of
gene expression. As a reciprocal experiment, purified embryonic
myoblasts were isolated and infected by a lentiviral vector ex-
pressing the Nfix2 and Nfia1.1 isoforms (or an empty vector, as
a control). After 3 days in culture, the Nfix2-embryonic myoblasts
(Nfix2) formed larger myotubes with an increased fusion index
(Figure 1E) in comparison with control cells (CTL) (Figure 1B).
In contrast, induction of Nfia1.1 reduced myoblast fusion
(Figures 1B and 1E). RT-PCR analysis showed that Nfix2- but
not Nfia1.1-differentiated myotubes expressed the fetal marker
b-enolase and downregulated expression of the slow MyHC;
unexpectedly, MCK, the other fetal marker analyzed, was not
expressed (Figure 1C), suggesting the requirement of a cofac-
tor(s) for Nfix2-mediated induction of MCK. In approaches of
both loss and gain of function, myogenin was not dramatically
affected (data not shown), suggesting that Nfix modulates
fetal/embryonic gene expression independently from its role ofCell 140, 554–566, February 19, 2010 ª2010 Elsevier Inc. 555
Figure 1. Nfix2 Modulates Embryonic and Fetal Muscle Genes
(A) Analysis by immunofluorescence of muscle differentiation of the Nfix ko//Myf5GFP-P/+- and Myf5GFP-P/+-purified fetal myoblasts (E16.5), the latter infected by
Lentivector expressing the siRNA for Nfix (siNfix) or Nfia (siNfia), compared to nontargeting control (CTL). Cells are stained with anti-MyHC, antibody (green) and
DAPI (blue). The scale bar represents 100 mm.
(B) Immunofluorescence on Myf5GFP-P/+-purified embryonic myoblasts (E11.5) infected by lentiviruses expressing the HA-Nfix2 (Nfix2), the HA-Nfia1.1, or the
empty vector (CTL), as control, stained with anti-MyHC (green), HA (red) antibody, and DAPI (blue). The insert in the Nfix2-infected cells highlights the increased
fusion index (arrow). The scale bar represents 100 mm.
(C) RT-PCR on differentiated fetal (CTL, Nfix ko, siNfix, and siNfia) and embryonic myoblasts (CTL, Nfix2, and Nfia1.1) analyzing the expression of embryonic and
fetal markers following Nfix2 or Nfia1.1 modulation.
(D) qRT-PCR on fetal myoblasts infected by Lenti-siNfix or Lenti-siNfia analyzing the relative Nfis mRNA levels after Nfix or Nfia silencing.
(E) Fusion index of the differentiated fetal (CTL, Nfix ko, siNfix, and siNfia) and embryonic myoblasts (CTL, Nfix2, and Nfia).
The scale bars represent means of three experiments ± s.d. * (p < 0.05) and ** (p < 0.01) indicate significantly different from control (CTL). See also Figure S1 and
Table S1.coactivator of myogenin. To identify other genes potentially
modulated by Nfix2, we performed a quantitative real-time
PCR for 95 muscle characteristic genes on the transduced
myoblast populations (Engr and NfiEngr fetal myotubes, CTL
and Nfix2-embryonic myotubes). The results showed that the
induction of Nfix2 activatedmany genes in embryonicmyotubes,
while NfiEngr inhibited a more restricted number of genes in fetal556 Cell 140, 554–566, February 19, 2010 ª2010 Elsevier Inc.myotubes (respectively, 68 and 43 genes present a fold change
>2). Genes known to be specific of fetal muscle (e.g., MCK,
integrin-alpha7, b-enolase, and PKCq) were downregulated in
NfiEngr fetal myotubes; in addition, other genes such as M-cad-
herin, FGFR4, decorin, a-sarcoglycan, dystroglycan-1, and des-
min were also downregulated. Most of these genes were
induced in embryonic myotubes expressing Nfix2. Interestingly,
Figure 2. Nfix2 Forms a Complex with
Mef2A and PKCq
(A) Nfi was precipitated (IP) in extracts of C2C12
myotubes with anti-Nfi rabbit polyclonal antibody.
The immune precipitate was separated by SDS-
PAGE and reacted with anti-Mef2A and Mef2C
antibodies. Immunoprecipitation with nonrelated
rabbit IgG (IgGr) was performed to show the spec-
ificity of the assay.
(B) C2C12 cells were transfected with a plasmid
vector expressing HA-Nfix2 plasmid, immunopre-
cipitated (IP) with anti-HA antibody, separated by
SDS-PAGE, and probed with anti-Mef2A and
anti-Mef2C antibodies.
(C) C2C12 cells were transfected with plasmid
vectors expressing HA-Nfia1.1, HA-Nfib2, or
HA-Nfic and the different Nfis were immunopre-
cipitated (IP) with anti-HA antibody, separated by
SDS-PAGE, and probed with anti-Mef2A and
anti-Mef2C antibodies.
(D) BiFC assay. C2C12 cells were transfected
with vectors expressing YNm9-Mef2A and
YC155-Nfix2. Thirty-six hours after transfection,
YFP fluorescence accumulated in the nucleus,
demonstratingMef2A andNfix2 binding. The scale
bar represents 100 mm.
(E) C2C12 cells were transfected with plasmid
vector expressing HA-Nfix2 and immunoprecipi-
tated (IP) with anti-HA antibody. The binding
among Nfix, Mef2A, and PKCq was tested with
specific anti-Mef2A and anti-PKCq antibodies.
(F) The JEG3 cell line was cotransfected with both
Mef2A-flag and PKCq plasmids. Mef2A was
immunoprecipitated with anti-flag antibody, and
binding with PKCq was tested. The absence of
binding between PKCq and Mef2A was rescued
after cotransfection of the JEG3 cells with HA-
Nfix2 plasmid (see arrow).
(G) PKCq kinase assay on C2C12 myoblasts.
PKCq was immunoprecipitated (IP) in C2C12 cells
transfected with the empty vector (CTL) or trans-
fected with HA-Nfix2 plasmid. The amount of
PKCq and Nfix (by anti-HA antibody) in the immu-
noprecipitates was assessed bywestern blot (left).
The activity was assayed by phosphorylation of
GST-Mef2A fusion protein, histone H1 (H1, as
positive control), and GST-Rb fusion protein (Rb,
as negative control).
IP, immunoprecipitated; T, total lysate; CTL,
control.proteins responsible for sarcomere contraction (i.e., the tro-
ponin/tropomyosin complex) were strongly upregulated in these
myotubes. Details are presented in Table S1. These data indi-
cate that Nfix2 is a key regulator of the transcriptional switch of
many embryonic/fetal muscle genes.
Fetal MCK Expression Depends upon Cooperation
between Nfix2, Mef2A, and PKCq
We reported previously that Mef2 transcription factors are ex-
pressed both in embryonic and fetal muscle but bind the MCK
proximal enhancer region only in the fetus as a consequence
of stage-specific Mef2 phosphorylation (Ferrari et al., 1997).
We had also shown that the q isoform of PKC is expressed in fetalmuscle (Zappelli et al., 1996), but whether this isoform is respon-
sible for the direct phosphorylation of Mef2 had not been evalu-
ated. Thus, we initially tested whether Nfi was able to bind Mef2,
and in particular the forms predominantly expressed in muscle,
Mef2A and Mef2C, by coimmunoprecipitating the endogenous
Nfi in C2C12 cells. As Figure 2A shows, Nfi is able to specifically
bind Mef2A but not Mef2C. As the antibody we used did not
discriminate the different members of the Nfi family, we trans-
fected C2C12 myoblasts with the HA-tagged Nfix2 expression
vector and immunoprecipitated Nfix2 containing complexes
with an anti-HA antibody (Figure 2B). The same approach was
followed with vectors expressing the HA-Nfia1.1, HA-Nfib2, or
HA-Nfic2 isoforms (Figure 2C). The coimmunoprecipitationsCell 140, 554–566, February 19, 2010 ª2010 Elsevier Inc. 557
Figure 3. Nfix2, PKCq, and Mef2A Cooperate in
MCK Transactivation
(A) Immunofluorescence on Myf5GFP-P/+-purified embry-
onic myoblasts (E11.5) cotransfected with HA-Nfix2 and
PKCq plasmids (HA-Nfix2/ PKCq) or the empty vector as
control (CTL) showing MyHC (green), HA (red), and DAPI
staining (blue). The scale bar represents 100 mm.
(B) Western blot on the HA-Nfix2/ PKCq or CTL embryonic
differentiated myoblasts. GAPDH was chosen to
normalize the amount of proteins loaded.
See also Figure S2.clearly revealed that Nfix2 is the only member of the Nfi family
able to bind Mef2A. To further confirm this result, we used the
bimolecular fluorescence complementation (BiFC) approach
(Saka et al., 2008), which allows detection of protein-protein
interactions in living cells. To this end, Nfix2 and Mef2A were
fused to the amino(N)- or carboxy(C)-terminal of the yellow fluo-
rescent protein (YFP), respectively, and transfected into C2C12
myoblasts. Coexpression of YNm9-Mef2A and YC155-Nfix2 in
C2C12 cells resulted in complementation of the YFP, indicating
in living cells that Nfix2 directly interact withMef2A in the nucleus
of living cells (Figure 2D), while no complementation occurred
when the YN fragment alone was expressed in association
with Mef2A-YC (data not shown).
We then testedwhether PKCq could be immunoprecipitated in
HA-Nfix2-expressingC2C12myoblasts, and thepossiblebinding
to Nfix2 and/or Mef2A was evaluated. As shown in Figure 2E,
Nfix2 was able to bind not only Mef2A but also PKCq. This result
prompted us to determine whether Mef2A was bound directly to
PKCq or whether this binding was Nfix2 mediated. To address
this point,we used the JEG3cell line,which expresses essentially
no Nfi proteins. JEG3 cells were cotransfected with both Mef2A-
flag and PKCq, andMef2A was immunoprecipitated with an anti-
flag antibody. It appeared that Mef2A and PKCqwere not able to
bind directly to each other, while bindingwas rescued in the pres-
ence of Nfix2 (Figure 2F), suggesting that Nfix acts as a bridge
betweenMef2AandPKCq, likely to allowMef2Aphosphorylation.
To investigate this point, we performed a PKCq kinase assay on558 Cell 140, 554–566, February 19, 2010 ª2010 Elsevier Inc.control and HA-Nfix2-expressing C2C12 cells.
The kinase activity of the immunoprecipitated
PKCq was tested using as possible substrates
Mef2A, histone H1 (as a positive control), or reti-
noblastoma protein (pRB, as a negative control).
As shown in Figure 2G, PKCqwas able toweakly
phosphorylate Mef2A, but this ability was
strongly enhanced in the presence of Nfix2. To
test whether the ternary complex among
Mef2A, Nfix2, and PKCq was responsible for
MCK transactivation in fetal myotubes, we co-
transfected purified-embryonic myoblasts with
both Nfix2 and PKCq and allowed them to
differentiate in vitro. The resulting myotubes
showed a typical fetal morphology, even more
pronounced than that after induction of Nfix2
alone (compare Figure 3A with Figure 1B).
Most importantly, Nfix2- and PKCq-coexpress-ing myotubes expressedMCK (Figure 3B). A chromatin immuno-
precipitation (ChIP) assaywas then performed on embryonic and
fetal myotubes. In the case ofMCK, we tested two different puta-
tive Nfix binding regions (according the Genomatix MatInspector
database) (Cartharius et al., 2005), MCK-2500/-2400 and MCK-
1200/-1048, close to the Mef2 box domains. For b-enolase, we
used the well-characterized region located at +504/+637 from
the transcription starting site (Feo et al., 1995). As shown in
Figures S2A and S2B, neither Nfi nor Mef2A were able to bind
to MCK and b-enolase enhancer/promoters in nuclear extracts
of embryonic (E11.5) myotubes, while this binding was detected
in extracts of fetal (E16.5) myotubes. Moreover, ChIP assay
performed on HA-Nfix2-expressing fetal myotubes (E16.5
HA-Nfix2) confirmed the direct binding of Nfix on MCK and
b-enolase enhancer/promoter (Figure S2C), while the PKCq
seems only to participate in Mef2A phosphorylation not being
detectable in the complex on MCK and b-enolase regulatory
regions (Figure S2D).
Together, these results demonstrate the existence of aMef2A/
Nfix2/PKCq complex responsible for MCK transactivation and
that Nfix acts as a regulator of fetal myogenesis by different
molecular mechanisms.
Fetal Skeletal Muscle Deficient forNfixDisplays Defects
in Myogenesis and a Delayed Sarcomerogenesis
To confirm the results obtained in in vitro and ex vivo experi-
ments, we studied fetal myogenesis in the Nfix-deficient mouse.
Since Nfix is expressed in different tissues and theNfix knockout
mouse shows brain and other malformations (Driller et al., 2007),
we conditionally ablated Nfix in skeletal muscle. To this aim, we
crossed the floxed Nfixc/+ mouse (Campbell et al., 2008) with the
MyoD-Cre transgenicmice (F3/-2,5cre) (Chen et al., 2005); in this
mouse, the expression of the Cre recombinase is under the
control of the regulatory sequences of the muscle specific
gene MyoD. While muscle-specific Nfix-deficient embryos
(E11.5) were indistinguishable from wild-type (WT) littermates
(Figure S3), at E16.5 muscle-specific Nfix null fetuses were
smaller than the WT even though their gross morphology was
apparently normal (Figure 4A). Hematoxylin and eosin (H&E)
staining on hind-limb sections revealed dramatic disorganization
of muscle fibers in Nfix null fetuses (Figure 4B). Transmission
electron microscopy (TEM) on hind-limb sections from WT and
Nfix null fetuses showed poorly assembled sarcomeres in the
Nfix-deficient versus WT fetuses (Figure 4C), consistent with
H&E staining (Figure 4B), likely due to a delay in sarcomere orga-
nization since at P3 the sarcomeres appeared to be indistin-
guishable from WT (Figure 4D). Western blot analysis on the
different Nfix null and WT fetuses confirmed the in vitro data:
Nfix-deficient fetuses showed downregulation of b-enolase and
MCK but persistent expression of slow MyHC (Figure 4E). Inter-
estingly, Myogenin expression was not decreased in Nfix null
fetuses. Immunofluorescence on muscle sections with anti-
bodies directed against all sarcomeric or slow MyHC confirmed
the data from western blots (Figure 4I). To explain the different
phenotype of the Nfix null fetus, we tested whether changes in
size may be due to altered proliferation (Ki67 staining), apoptosis
(ApoTag detection), or fiber number, but no significant differ-
ences were noticed (data not shown). However, a reduced
amount ofMyHC/fetus was detected in theNfix-deficient fetuses
in comparison with their WT siblings (Figure 4G), which corre-
sponded to reduced cross-sectional area of the MyHC positive
fibers (Figures 4F and 4H), whose number was unchanged
(data not shown).
These data show that besides its role in regulating the transi-
tion from the embryonic to the fetal program, Nfix plays an
important role in sarcomere organization depending, at least in
part, upon the expression of the mature isoforms of contractile
proteins.
Nfix2 Is Required In Vivo to Drive the Developmental
Shift from Embryonic to Fetal Myogenesis
We then analyzed the gain of Nfix function in transgenic mice
overexpressing Nfix during embryonicmyogenesis (E12.5) under
the transcriptional control of the myosin light chain 1F promoter/
enhancer (Jiang et al., 2002) (Figure S4A). Different founders
originated independent lines indistinguishable from each other
(Figure S4B). Transgenic mice showed no overt differences in
terms of fertility, behavior, and life span with respect to the litter-
mate controls. We tested the expression of Nfix2 in transgenic
embryos (Nfix2) at E12.5 by RT-PCR using primers specific for
Nfix2 and for the other members of the Nfi family (Figure S4C).
As expected, the expression of Nfix2 but not of the other family
members was much greater in the transgenic embryos than in
WT littermates. At E12.5, Tg:Mlc1f-Nfix2 embryos were larger
in size than the WT littermates (Figure 5B, a and b). H&E stainingof muscle fibers did not reveal obvious differences between WT
and transgenic embryos (data not shown), while TEM hind-limb
sections showed an almost completely organized sarcomero-
genesis (Figure 5B, c and d, see Z bands) in transgenic embryos,
with an apparent precocious maturation in comparison with WT
embryos. The amount of MyHC accumulation together with the
increased fiber size (as shown in the forelimb transverse sections
of the Tg:Mlc1f-Nfix2 embryos, Figures 5D and 5E) may in part
explain the increased size of transgenic mice. Interestingly,
transgenic embryos have much increased levels of Igf-1
(Figure 5F), which is known to affect prenatal growth (Liu et al.,
1993). No differences in proliferation or apoptosis were noticed
(data not shown). In Figure 5A, western blot analysis of WT
and Tg:Mlc1f-Nfix2 embryos revealed premature expression of
b-enolase and downregulation of slow MyHC (the latter
confirmed by immunofluorescence on a limb muscle section,
Figure 5C). In accordance with in vitro observations, premature
Nfix2 expression was not sufficient to promote MCK expression.
To test in vivo for an Nfix/Mef2A requirement for PKCq in
inducing MCK expression, we generated a Tg:Mlc1f-PKCq
transgenic mouse by using the same strategy designed for the
Tg:Mlc1f-Nfix2 mouse (Figure S4D). Different founders (Fig-
ure S4E) were crossed with the Tg:Mlc1f-Nfix2 with the aim of
examining MCK expression in the double-transgenic Tg:Mlc1f-
Nfix2//Tg:Mlc1f-PKCq embryos. Unexpectedly, no embryos of
the appropriate genotype were obtained from these crosses
(although different founders were tested); the reason for this
observation remains unclear. To overcome this problem, we
established cocultures of embryonic myoblasts from Tg:Mlc1f-
Nfix2 and Tg:Mlc1f-PKCq embryos, reasoning that fusion of
the two different transgenic myoblasts would lead to coexpres-
sion of Nfix and PKCq in the same cell. After 3 days in culture, the
mixed population differentiated properly (Figure 5G), and MCK
was expressed only in the cocultured Tg:Mlc1f-Nfix2 and
Tg:Mlc1f-PKCq myotubes (Figure 5H), formally demonstrating
the cooperation of Nfix2 and PKCq in the induction of MCK.
Nfix2 Regulates SlowMyHCExpression throughNFATc4
Beside its role of transcriptional activator, Nfix is also able to
negatively modulate the expression of embryonic genes, such
as slow MyHC. We thus tested whether Nfix directly binds to
the promoter of slow MyHC. The 5 kb region upstream of the
transcription starting site of murine, rat, and human slow
MyHC were analyzed with Genomatix, but no conserved puta-
tive binding sites were identified, and a ChIP assay for Nfix2
failed to detect direct binding (Figure 6C), suggesting the exis-
tence of an indirect mechanism through which Nfix inhibits
slow myosin.
It was recently shown that transcription of slow MyHC in adult
muscle depends on the NFAT family members NFATc1–4 (Cala-
bria et al., 2009). The NFATc4 isoform is more expressed in
embryonic than in fetal myoblasts (Biressi et al., 2007b), and
its expression dramatically changed after Nfix modulation in
myoblasts (Table S1); we thus tested whether Nfix could repress
slow MyHC expression by modulating the transcription of
NFATc4. Myf5GFP-P/+-purified fetal myoblasts were transfected
with a NFATc4-expressing vector, and the amount of slow
MyHC versus the expression of all sarcomeric myosins wasCell 140, 554–566, February 19, 2010 ª2010 Elsevier Inc. 559
Figure 4. Phenotype, Muscle Morphology, and Gene Expression of the Skeletal Muscle-Specific Nfix -Deficient Fetuses
(A) Morphology of the skeletal muscle-specific Nfix-deficient and WT fetus at E16.5
(B) H&E staining on serial transverse sections of hind limbs of skeletal muscle-specific Nfix-deficient and WT fetus at E16.5. The scale bar represents 50 mm.
(C and D) Transmission electron microscopy (TEM) on serial transverse sections of hind limbs of skeletal muscle-specific Nfix-deficient andWT fetus at E16.5 (C)
and at P3 (D). The scale bar represents 2 mm.
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evaluated. As Figures 6A and 6B show, NFATc4-expressing cells
differentiated similarly to CTL cells, but robustly expressed slow
MyHC. A ChIP assay performed on HA-Nfix2-expressing fetal
myotubes (E16.5 HA-Nfix2) demonstrated direct binding of
Nfix on the promoter of NFATc4 (Figure 6C). These data suggest
that Nfix negativelymodulate the expression of NFATc4, which in
turns is responsible for the normal expression of slow MyHC.
Pax7 Is Sufficient but Not Required for the Induction
of Nfix
To date, the regulation of Nfix gene expression is completely
unknown. Since Pax7 expression levels are higher in
Myf5GFP-P/+-purified fetal myoblasts than in their embryonic
counterpart (Biressi et al., 2007b) and Pax7+ cells give rise to
and are required for fetal myogenesis (Hutcheson et al., 2009),
we investigated a possible role of Pax7 in regulating the fetal-
specific expression of Nfix. To this aim, E11.5 Myf5GFP-P/+-
purified embryonic myoblasts were transduced with pLentiPax7
lentivector after 2 days in culture, they robustly expressed Nfix
(Figures 7A and 7B). Moreover, a ChIP assay on unpurified HA-
Pax7-expressing fetal myotubes (E16.5 HA-Pax7) revealed that
Pax7 directly binds, with different affinity, to four putative Pax7
binding sites identified by Genomatix MatInspector analysis on
the promoter of Nfix (Figure 7C). On the other hand, the expres-
sion of Nfix in limbs of E16.5 Pax7/ mice was only modestly
decreased, and it was normal in postnatal (P14) Pax7 null muscle
(Figure 7D), suggesting that other genes besides Pax7 may acti-
vate Nfix during fetal and perinatal development.
DISCUSSION
Progressive changes in size and shape characterize the devel-
opment of most vertebrate organs and tissues. These changes
often reflect transcriptional modulation of stage (and tissue)-
specific genes, according to a complex developmental program,
evolved to express genes that best fit the changing needs of the
developing organism. These genes are often developmentally
regulated isoforms, usually evolved in vertebrates from a
common ancestral gene. For example hemoglobin expression
switches from an embryonic, to a fetal, to an adult form (Peter-
son, 2003) to optimize gas exchange with embryonic, fetal,
and adult tissues, respectively. The transcriptional regulation of
this switch is very complex and involves several proximal and
distant regulatory elements (Palstra et al., 2008). Several other
gene families, such as myosins and troponins (Gillis et al.,
2007), are similarly regulated in development, but little is known
about the relative molecular regulation.(E) Western blot analysis of extracts from two different skeletal muscle-specific
normalize the amount of proteins loaded.
(F) Immunofluorescence analysis on hind-limb transverse sections of Nfix-deficien
(green). The scale bar represents 100 mm.
(G) Quantification by western blot of MyHC content per fetus in the skeletal musc
same amount of each fetus extracted in the same volume of lysis buffer.
(H) Frequency histogram showing the CSA distribution of myofibers in WT (n = 8
(I) Immunofluorescence analysis on hind-limb sections of skeletal muscle-specific
slow MyHC (green) and with DAPI (blue). The scale bar represents 100 mm.
See also Figure S3.In this work, we identify a major molecular mechanism that
controls the switch from embryonic to fetal gene transcription
in mammalian skeletal muscle. We show that the transcription
factor Nfix, expressed in fetal but not in embryonic muscle, acti-
vates transcription of fetal-specific genes while repressing
expression of the embryonic specific genes.
Pax7 is sufficient to activate Nfix (and thus the fetal program) in
embryonic myoblasts but is not strictly necessary because in
fetal and neonatal limbs of Pax7 null mice Nfix is modestly
reduced or normal. The only partially overlapping patterns of
expression shown by Pax7 and Nfix during organogenesis
(Chaudhry et al., 1997; Jostes et al., 1990) further corroborate
the idea that additional genes can also be responsible for Nfix
expression.
Nfix is required and sufficient to modulate expression of a
number of genes, such as slow myosin, troponins, M-cadherin,
a7-integrin, LDH, FGFR4, and MCK. Interestingly, modulation
of Nfix levels in purified-embryonic and fetal myoblasts pro-
duced modest alterations in the differentiation potential per se,
but induced a fine-tuning of the fetal program of muscle gene
expression, causing the observed morphological changes:
fetuses lacking Nfix in skeletal muscle are smaller and have
fibers with reduced diameter, whereas embryos prematurely
expressing Nfix are larger, likely reflectingmore robust transcrip-
tion in fetal muscle. Interestingly, expression of Igf-1, a major
regulator of embryonic growth (Liu et al., 1993), is strongly
induced in Tg:Mlc1f-Nfix2 embryos.
Nfix-deficient fetuses also showed disorganized sarcomero-
genesis, likely due to a delayed assembly of sarcomeres as post-
natal sarcomeres of the mutant mouse are normal. It is possible
that this phenomenonmay depend on the persistence of cardiac
troponin C and absence of skeletal isoforms, since perturbed
expression of troponins has been shown to induce sarcomere
abnormalities (Siedner et al., 2003).
Like other transcription factors, Nfix acts as a transcriptional
activator or repressor, likely depending upon interacting pro-
teins. It is possible that Nfix directly bind its consensus on the
DNA of some embryonic/fetal genes to directly activate or
repress their transcription with its C-terminal domain; for other
genes, such as MCK, it may recruit other proteins (PKCq/
Mef2A) on embryonic and fetal muscle promoters. It is likely
that Nfix may act with a similar mechanism on additional genes
that were not overtly modulated in our real-time PCR screening
because of the lack of coactivation by either Mef2A/PKCq or
other partners yet to be identified. The role of Nfix as a transcri-
tional repressor remains to be elucidated. We have shown that it
does not bind directly the slow MyHC promoter but ratherNfix null (#8, 9) and two WT (#4, 10) fetuses at E16.5. GAPDH was used to
t and WT fetuses at E16.5 stained with antibodies anti-MyHC (red) and laminin
le-specific Nfix-deficient and WT fetuses. Each lane has been loaded with the
67 myofibers) and Nfix-deficient (n = 870 myofibers) fetuses at E16.5.
Nfix-deficient and WT fetuses at E16.5, stained with antibodies anti-MyHC or
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Figure 5. Phenotype, Muscle Morphology, and Gene Expression of Tg:Mlc1f-Nfix2 Embryos at E12.5 of Development
(A) Western blot analysis of extracts from Tg:Mlc1f-Nfix2 and WT embryos at E12.5. GAPDH was used to normalize the amount of proteins loaded.
(B) Tg:Mlc1f-Nfix2 (b) and WT (a) embryos at E12.5. Transmission electron microscopy (TEM) on serial transverse sections of forelimbs of Tg:Mlc1f-Nfix2 (d) and
WT (c) embryos at E12.5. The scale bar represents 2 mm.
(C) Immunofluorescence on forelimb sections of Tg:Mlc1f-Nfix2 andWT embryos at E12.5, using antibodies anti-MyHCor anti-slowMyHC (green) andDAPI (blue)
to stain the nuclei. The scale bar represents 100 mm.
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Figure 6. Slow MyHC Regulation through Nfix2-
Dependent NFATc4 Expression
(A) Immunofluorescence analysis of slow MyHC expres-
sion in Myf5GFP-P/+-purified fetal myoblasts (E16.5) trans-
fected with NFATc4-expressing vector (NFATc4) com-
pared to the empty vector (CTL). Cells are stained with
anti-slow MyHC (green), anti-all sarcomeric MyHCs (red)
and DAPI (blue). The scale bar represents 100 mm.
(B) Slow MyHC expression analyzed by RT-PCR analysis
of in the Myf5GFP-P/+-purified fetal myoblasts expressing
NFTAc4 (NFATc4).
(C) ChIP assay on unpurified fetal myoblasts transduced
by HA-Nfix2 lentivirus to test Nfix2 binding (by using the
anti-HA antibody) on slow MyHC or NFATc4 promoters.
b-actin has been used as a negative control and IgG
as an unrelated antibody. I, input; no Ab, not antibody.
ChIP with anti-MyoD antibodies was used as positive
control.represses transcription of NFATc4 a protein responsible for acti-
vation of this gene. A schematic model of the possible mecha-
nisms through which Nfix acts is shown in Figure 7E.
Although no skeletal muscle defects were reported (Driller
et al., 2007; Campbell et al., 2008), the Nfix-deficient mice are
significantly smaller than their WT counterparts and the cause
of their premature lethality is still not completely understood.
The conditional ablation of Nfix in skeletal muscle allowed us
to highlight specific defects in fetal myogenesis. Interestingly,
skeletal muscle-specific Nfix-deficient mice are also smaller
than their WT littermates.
From the data presented here, it appears that Nfix is essential
for the expression of fetal markers such as MCK, b-enolase,
PKCq, or the troponin/tropomyosin complex, thus ensuring the
appropriate enzymatic and contractile apparatus normally
required for fetal and postnatal muscle. Moreover, the Nfix-
dependent expression of a7-integrin, already known as a fetal
marker (George-Weinstein et al., 1993; Biressi et al., 2007b),
and of M-cadherin, important for myoblast fusion (Kaufmann
et al., 1999), may modulate the selective fusion of myoblasts
with either primary or secondary fibers, necessary to form the
adult myofiber pattern.
Our observations, aswell as those fromprevious studies, point
to a dual role for Nfix inmyogenesis. It cooperates withmyogenin
in the transcriptional activation of muscle genes, as originally(D) Quantification by western blot of MyHC content per fetus in the Tg:Mlc1f-Nfix
fetus extracted in the same volume of lysis buffer.
(E) Immunofluorescence analysis on hind-limb transverse sections of the Tg:Mlc1
(green). The scale bar represents 100 mm.
(F) Igf-1 expression analyzed by RT-PCR of RNA extracts from Tg:Mlc1f-Nfix2 (#
(G) Immunofluorescence analysis of cocultures of Mlc1f-Nfix2 and Tg:Mlc1f-PKC
using the antibody against the MyHC (green) and DAPI (blue) to stain the nuclei.
(H) MCK is induced in Tg:Mlc1f-Nfix2/Tg:Mlcif-PKCq embryonic myotubes as ass
Tg:Mlc1f-PKCq (X2/q) embryonic myoblasts (E12.5) after 2 and 3 days.
Mabs, myoblasts. See also Figure S4.described by Funk and Wright (1992). This function is shared
by many different genes that directly or indirectly promote
myogenesis. On the other hand, Nfix is the only gene so far
identified that specifically represses expression of embryonic
genes and activates expression of fetal genes in fetal muscle.
In embryonic mammalian muscle, slow myosin heavy chains
and ubiquitous isoforms of metabolic enzymes contribute to a
slow twitching, low performant contractile activity; in the fetus,
fast contractile proteins together with muscle-specific isoforms
of metabolic enzymes, required to produce high level of ATP,
result in fast twitching contraction.
Nfi transcription factors are well-conserved proteins across
different species. In particular, there are four NFI genes in
mammals and birds (NFIA, NFIB, NFIC, and NFIX) and a single
NFI gene in Drosophila, C. elegans, Anopheles, sea urchin, and
other invertebrates (Kruse et al., 1991; Gronostajski, 2000). No
NFI genes have been found in plants, bacteria, or single-cell
eukaryotes. Our preliminary data indicate that the Nfix and
Mck (cmka) genes in the developing zebrafish are expressed
at the onset of myogenesis, when fast MyHC is promptly
expressed in the large majority of skeletal muscles. This has
evolutionary relevance. A progressive maturation of skeletal
muscle is probably useful for tetrapods, which first develop
muscle anlagens with a complex tridimensional pattern, then
increase themusclemass by formation of secondary (fetal) fibers2 and WT embryos. Each lane has been loaded with the same amount of each
f-Nfix2 and WT embryos, stained with antibodies anti-MyHC (red) and laminin
1, 3) and WT (#4, 8) embryos at E12.5.
q embryonic myoblasts (E12.5) after 3 days in culture. The staining was done
The scale bar represents 100 mm.
ayed by RT-PCR on unpurified single (X2 and q) and coculturedMlc1f-Nfix2 and
Cell 140, 554–566, February 19, 2010 ª2010 Elsevier Inc. 563
Figure 7. Nfix Regulation by Pax7 and Proposed
Model for Nfix Action
(A and B) Nfix induction analyzed by semiquantitative
(A) and real-time (B) RT-PCR on Myf5GFP-P/+-purified
embryonic myoblasts (E11.5) infected with lentivector
expressing Pax7. CTL, control. Overexpression of Pax7
was verified with RT-PCR (A).
(C) ChIP assay on unpurified fetal myoblasts transfected
with pCMV.HAPax7 (HA-Pax7) to test Pax7 binding (by
using the anti-HA antibody) on four different regions on
the Nfix promoter. b-actin has been used as a negative
control and IgG as an unrelated antibody. I, input; no Ab,
not antibody.
(D) Real-time RT-PCR showing the Nfix mRNA levels
on E16.5 WT and Pax7 null, P14 WT and Pax7 null
RNA extracts. Error bars represent means of three exper-
iments ± standard deviation.
(E) Model of the possible mechanisms through which Nfix
acts in modulating embryonic and fetal genes.and finally increase progressively the fiber size by fusion of
subsequent generations of myoblasts. Mammals and birds
develop in a protected environment and show an initially slow
muscle phenotype. In contrast, zebrafish embryos acquire
motility when they are still in the chorionmembrane (22–24 hours
postfertilization [hpf]) and begin to swim rapidly (48 hpf). In this
species, developing muscle fibers are predominantly fast twitch-
ing, andmuscle-specific isoforms of metabolic enzymes such as
MCK are expressed at the onset of myogenesis, as is its regu-
lator, Nfix. Therefore, a direct causal correlation between Nfix
expression and a fetal/fast myogenic program seems to be
conserved from zebrafish to mouse while the timing of Nfix
differs, in apparent correlation with their particular lifestyles.
Although further work will be required to clarify the develop-
mental role of Nfix in vertebrate evolution, the in vitro and
in vivo data presented here conclusively demonstrate that in
the mouse, Nfix acts as a positive regulator of the fetal (fast)
myogenic program. The function of Nfix in postnatal growth
and regeneration, as well as the identification of genes that
contribute (together with Pax7) to the activation of Nfix in the
late embryonicmuscle, remain open questions for future studies.564 Cell 140, 554–566, February 19, 2010 ª2010 Elsevier Inc.EXPERIMENTAL PROCEDURES
Cell Cultures/Cell Isolation
C2C12 myoblasts and JEG3 chorion carcinoma cell line
were grown as detailed in the Extended Experimental
Procedures. Embryonic and fetal myoblasts were isolated
from Myf5GFP-P/+ mice (Kassar-Duchossoy et al., 2004) as
previously described (Biressi et al., 2007b). Unpurified
embryonic and fetal myoblasts were obtained from
CD-1, Tg:Mlc1f-Nfix2, or Tg:Mlc1f-PKCq embryos/fetuses
via the same procedure/enzymatic digestion utilized for
the Myf5GFP-P/+-sorted myoblasts. In the coculture exper-
iment, unpurified embryonic myoblasts from the Tg:Mlc1f-
Nfix2 or Tg:Mlc1f-PKCq E11.5 embryos were obtained
and mixed at a ratio 1:1. The short trypsinization assay
was performed as described in Kitzmann et al. (1998).
Mutant Animals and Genotyping
The Myf5GFP-P/+ mice (Kassar-Duchossoy et al., 2004),
MyoDCre mice (Chen et al., 2005), Nfixc/+ mice(Campbell et al., 2008) and Pax7/ mutant mice (Seale et al., 2000) and their
genotyping strategies have been published.
Transgenic Tg:Mlc1f-Nfix2 and Tg:Mlc1f-PKCq mice were generated as
detailed in the Extended Experimental Procedures. Expression of the trans-
gene in the various tissues was evaluated by RT-PCR. All experiments were
performed under internal regulations for animal care and handlings (IACUC
355).
Plasmids
The plasmids used were as follows: pMef2AFlag and pMef2CFlag (kindly
provided by S.Molinari, Modena), pNfiEngrailed and pEngrailed (kindly
provided by C. Bachurski), pPKCq (kindly provided by Marina Bouche`),
pcDNA3NFATc4 (kindly provided by S. Schiaffino), pLKO.1siNfix and
pLKO.1siCONTROL (Darmacon, Open Biosystems), and pLentisiNfia
(kindly provided by Clara Nervi). The pCMVHA-Pax7 was obtained by cloning
of the Pax7 complementary DNA (cDNA) into the pCMV-HA plasmid
(Clontech).
pLentiHA-Nfix2, pLentiHA-NfiEngr, pLentiEngr, and the empty pLentiVector
have been produced by subcloning of the HA-Nfix2, the NfiEngrailed
and Engrailed cDNAs in the pLentiV5/TOPO (Invitrogen, Carlsbad, CA).
pLenti4TO/mPax7 (Pax7) was engineered with Gateway technology
(Invitrogen). Pax7 cDNA was amplified with a 50-CACC flanking sequence
and ligated into the pENTR/D TOPO vector. Entry vector was used for the final
step of recombination into the pLenti4TO destination vector. A HA-tagged
cDNA encoding murine Nfia1.1 was inserted into the lentiviral vector
pRRL.cPPT.hCMV.hPGK.GFP.WPRE under control of the CMV promoter.
The pYNm9-Mef2A and pYC155-Nfix2 plasmids were obtained as detailed
in the Extended Experimental Procedures.
Cell Transfection and Transduction
Purified embryonic and fetal myoblasts were transfected with the Lipofect-
amine LTX transfection Reagent (Invitrogen) and allowed to differentiate.
C2C12myoblasts and the JEG3 cell line were transfected using Lipofectamine
with Plus reagent (Invitrogen). Thirty-six hours after the transfection, cells were
processed for the coimmunoprecipitation assays. For the BiFC assay, C2C12
cells were transfected with the YNm9-Mef2A and YC155-Nfix2 plasmids, and
36 hr after transfection, they were incubated 30 min at 30C to enhance YFP’s
fluorophore maturation before the analysis.
The lentiviral particles were produced as detailed in the Extended Experi-
mental Procedures. Transduction of C2C12, embryonic, and fetal myoblasts
was performed by addition of the viral preparation. Polybrene was added for
the C2C12 cells (8 mg/ml, Sigma Aldrich). After overnight incubation, the
medium was changed. These preparations were used to infect C2C12
myoblasts at a multiplicity of infection (MOI) of 100 and purified embryonic/
fetal myoblasts at an MOI of 10.
Immunofluorescence on Cultured Cell and Tissue Sections
Cell cultures and 8 mm cryostat sections were fixed in 4% paraformaldehyde
for 10 min at 4C. When necessary, adjacent sections were stained with H&E.
Immunofluorescent staining was carried out with the following antibodies:
rabbit polyclonal (Biressi et al., 2007b) and mouse monoclonal (MF20,
DHSB) antibody to all sarcomeric MyHCs; mouse monoclonal slow MyHC
(BA-D5, DSMZ); mouse monoclonal HA.11 (Covance, Princeton, NJ); and
rabbit polyclonal laminin (Sigma). Secondary antibodies usedwere Alexa Fluor
488 or 594-conjugated donkey anti-mouse. DAPI was used to stain the nuclei.
Fiber Size Distribution
Morphometric analyses were performed on sections collected from similar
regions of embryonic or fetal limbs (onWT, null, or transgenicmice).The images
werecaptured fromeachsection, and Image1.63 (ScionCorporation)wasused
to determine the cross sectional area (CSA) of 700–1000myofibers per section.
Transmission Electron Microscopy
The samples were fixed for 2 hr at 4C with 4% paraformaldehyde and 2.5%
glutaraldehyde in 125 mM phosphate buffer. Samples were then postfixed
(1 hr) with OsO4 in 125 mM phosphate buffer, was washed and embedded
in Epon. Conventional thin sections were collected on uncoated grids, stained
with uranyl acetate and lead citrate, and examined with a Leo912 electron
microscope.
Western Blot, Coimmunoprecipitation, and Kinase Assay
The western blot, the coimmunoprecipitation and kinase assay were per-
formed as described previously (Messina et al., 2005).
For the coimmunoprecipitation, the antibodies used were rabbit anti-HA
(Santa Cruz), mouse anti-PKCq (BD Bioscience), mouse anti-flag (Sigma),
and rabbit anti-Nfi (Santa Cruz); normal rabbit IgG (Santa Cruz) was used as
control.
Western blot analysis of immunoprecipitates and total extracts was carried
out with the following antibodies: mouse anti-MyHC (MF20), mouse anti-slow-
MyHC (BA-D5, DSMZ), mouse anti-MCK (Abnova), mouse anti-b-enolase (BD
Bioscience), mouse anti-PKCq (BD Bioscience), mouse anti-Myogenin (F5D),
rabbit anti-Mef2C (Santa Cruz), rabbit anti-Mef2A (Santa Cruz), mouse anti-
HA (Covance, Princeton, NJ, USA), rabbit anti-Nfi (Santa Cruz), mouse anti-
btubulin (Covance, Princeton, NJ, USA), andmouse anti-GAPDH (Biogenesis).
PKCq-associated kinase activity is detailed in the Extended Experimental
Procedures.
ChIP Assay
The ChIP protocol was performed on unpurified embryonic (E11.5) and fetal
(E16.5) myoblasts as described (Molinari et al., 2004). The following antibodies
were used: rabbit anti-MEF2 (C21 sc-313X, 200 mg/0.1 ml, Santa Cruz), rabbitanti-Nfi (Santa Cruz), anti-PKCq (BD Bioscience), mouse anti-MyoD (Dako),
mouse anti-HA.11 (Covance, Princeton, NJ, USA), and, as a control, normal
rabbit IgGr (Santa Cruz). Immunoprecipitated DNA was subjected to PCR as
detailed in the Extended Experimental Procedures.
RT-PCR
The RNA frommouse embryos was isolated fromCD-1mice at different devel-
opmental stages. One microgram of RNA, collected from cells or tissues with
the RNeasy mini (or micro) kit (QIAGEN) or TRIZOL (Invitrogen) for tissues,
was converted into double-stranded cDNA with the cDNA synthesis kit
ThermoScript RT-PCR system (Invitrogen), according to the manufacturer’s
instructions. The primers used are described in the Extended Experimental
Procedures.
Quantitative Real-Time PCR
RNA was extracted and quantified as described above. Each tested RNA
sample was obtained by pooling of at least five independent RNAs extracted
from different experiments. cDNAs were reverse transcribed from total RNA
samples (100 ng per sample) with the High Capacity cDNA Archive Kit (Applied
Biosystems) as described in the manufacturer’s protocol. Details of the proce-
dure are described in the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and one table and can be found with this article online at doi:10.
1016/j.cell.2010.01.027.
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